Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Electrotherapy System Market - Insights
Electrotherapy system includes medical devices, which are used in management of chronic pain, wound healing, neuromuscular disorders, musculoskeletal disorders, and others. Electrotherapy works by relaxing the muscles, preventing and retarding disuse atrophy, and muscle rehabilitation. It is used by athletic trainers and therapists to treat athletic injuries. Moreover, in neuromuscular disorders, electrotherapy is used to support voluntary movement and build muscles through activation of muscle systems and neuromuscular facilitation.
Approval and launch of novel electrotherapy systems of neuromuscular diseases is expected to drive growth of the global electrotherapy system market
Key manufacturers such as Innovative Neurological Devices, Medtronic Plc. and others are focusing on extensive research and development and gaining regulatory approvals for their products. For instance, in March 2019, Innovative Neurological Devices received the U.S. Food and Drug Administration (FDA) approval for CERVELLA, a cranial electrotherapy stimulator for treating anxiety, insomnia, and depression.
In September 2018, Medtronic Plc. announced the U.S. Food and Drug Administration approval of Intellis Platform, a spinal cord stimulation used for managing different types of chronic intractable pain.
Moreover, in July 2013, DJO Global received the U.S. Food and Drug Administration approval for Empi Phoenix, it is used in patients undergoing anterior cruciate ligament (ACL) reconstruction, and total knee arthroplasty to avoid muscle atrophy. The device also helps in reducing swelling, and pain management.
The electrotherapy system market has been witnessing high demand which has led to the development of innovative electrotherapy systems. For instance, in September 2017, CEFALY Technology received the U.S. Food and Drug Administration approval for CEFALY, a medical device used for acute treatment of migraine in patients’ aged 18 years and above. CEFALY is an external trigeminal nerve stimulator (e-TNS) approved for use in migraine under prescription.
Increasing prevalence and incidence of chronic pain and neuromuscular diseases is expected to propel the global electrotherapy system market growth
Increasing incidence of neuromuscular disorders, owing to increasing problems such as weakening of muscle and nerves is expected to drive global electrotherapy system market growth. For instance, in 2015, the National Center for Biotechnology Information (NCBI) reported incidence rates for several neuromuscular disorders, which ranged from 0.05 to 9 per 100,000 population per year.
Moreover, increasing prevalence of migraine worldwide is expected to be a key factor driving the global electrotherapy system market growth. For instance, according to the National Center for Biotechnology Information (NCBI), in 2016, the global prevalence of migraine was 14.7% (1 out of 7 people).
The global electrotherapy system market size was valued at US$ 891.3 Mn in 2018 and is expected to witness a CAGR of 4.6% over the forecast period, (2019 – 2027).
Figure 1. Global Electrotherapy System Market Share (%), By End User, 2019 - 2027
Source: Coherent Market Insights Analysis (2019)
Regional segmentation of the global electrotherapy system market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold the dominant position in the global electrotherapy system market, owing to presence of key players such as Medtronic Plc., DJO Global Inc., Nevro Corporation, Cyberonics, Inc,, and others.
Furthermore, the Europe electrotherapy system market is expected to grow over the forecast period due to rising prevalence of chronic pain conditions, and neuromuscular diseases. For instance, according to the British Medical Journal (BMJ) 2016, prevalence of chronic pain in Europe ranged from 35.0% to 51.3%, prevalence of moderate disabling chronic pain ranged from 10.4% to 14.3% in adults, while prevalence of chronic pain in people in the age group of 18–39?years is 30%. Moreover, according to same source, chronic pain conditions occurs frequently in females in comparison to males.
Restrains of Global Electrotherapy System Market
Factors restraining the growth of global electrotherapy system market are availability of alternative treatment such as, drug treatment for chronic pain condition and neuromuscular disorders. There are few side effects of electrotherapy system such as skin irritation, rashes caused by adhesives used for electrodes, or the tape used for holding the electrodes in place, while over usage of electrotherapy system causes burning sensation in skin.
Figure 2. Global Electrotherapy System Market Share (%) Analysis, By Region, 2019 and 2027
Source: Coherent Market Insights Analysis (2019)
Key players operating in the global electrotherapy system market include Medtronic Plc., Zealmax Innovation Pvt Ltd, Zynex, Inc., DJO Global Inc., Nevro Corporation, Cyberonics, Inc., BTL Industries Inc., EMS Physio Ltd, STYMCO Technologies LLC, and Omron Healthcare Inc.